#ASH20: Out to shake up CML once again, Novartis lays out head-to-head between third-gen Gleevec scion and Pfizer rival
Novartis says its third-generation chronic myeloid leukemia drug — a scion to the fading blockbuster Gleevec — nearly doubled the response rate among patients who have progressed after two lines of treatment, paving the way to shake up the space once again.
The pharma giant reported a 25.5% major molecular response rate for asciminib at week 24, compared to 13.2% on Pfizer’s Bosulif (p=0.029). The asciminib arm also had more patients achieving a complete cytogenetic response; 40.8% did, versus 24.2% in the other group. In total, the trial enrolled 233 patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
